Welcome to our dedicated page for Arena Pharmaceuticals news (Ticker: ARNA), a resource for investors and traders seeking the latest updates and insights on Arena Pharmaceuticals stock.
Arena Pharmaceuticals reports corporate developments tied to its biopharmaceutical operations, including operating and financial results, clinical and regulatory disclosures, material agreements, and capital-structure matters. Company announcements have also covered shareholder voting and governance topics, including inducement restricted stock unit grants made under Nasdaq Listing Rule 5635(c)(4) and its Amended and Restated 2021 Long-Term Incentive Plan.
Arena Pharmaceuticals (Nasdaq: ARNA) announced its participation in several upcoming investor conferences. Key presentations include the Wells Fargo Virtual Healthcare Conference on September 9 at 1:20 PM ET, the Citi 2020 BioPharma Virtual Conference with investor meetings on September 10, the H.C. Wainwright Virtual Global Investment Conference on September 14 at 9:30 AM ET, and the Cantor Virtual Global Healthcare Conference on September 16 at 2:00 PM ET. Live audio webcasts will be available on their website, with replays for 30 days post-event.
Arena Pharmaceuticals (Nasdaq: ARNA) has initiated a Phase 2 trial for etrasimod, a novel oral treatment for moderate-to-severe alopecia areata, with the first subject dosed on September 1, 2020. The randomized, placebo-controlled trial involves 36 subjects over 24 weeks and aims to assess the drug's efficacy and safety. Etrasimod is designed to target immune responses linked to hair loss. The trial's primary endpoint is the change in Severity of Alopecia Tool (SALT) score. Results are expected in 2021, potentially addressing a significant unmet medical need.
Arena Pharmaceuticals (Nasdaq: ARNA) announced on August 15, 2020, the grant of inducement stock options and restricted stock units (RSUs) to five new employees. The stock options total 15,275 shares with an exercise price of $63.59, vesting over four years. The RSUs amount to 3,440 shares, also vesting over four years. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new hires in a competitive market.
Arena Pharmaceuticals reported Q2 2020 results, with revenues of $0, down from $1 million in Q2 2019. R&D expenses rose to $64.9 million, reflecting advancements in clinical trials, while G&A expenses increased to $22.9 million. The net loss expanded to $84.9 million, with a loss per share of $1.61 compared to $1.24 a year ago. Despite challenges from COVID-19, the company completed enrollment for the Phase 2b ADVISE trial and raised $301.8 million through an equity offering, boosting cash reserves to $1.3 billion. Future guidance remains consistent with a projected cash burn of $400-$430 million for 2020.
Arena Pharmaceuticals (Nasdaq: ARNA) will release its Q2 2020 financial results on August 5, 2020, after market close. A conference call will follow at 4:30 PM ET for investors and analysts to discuss the results. Interested parties can access the call by dialing (877) 643-7155 in the U.S. or (914) 495-8552 internationally, using conference ID 5343486. A live webcast will also be available on Arena's investor relations website, with a replay archived for 30 days post-event.
Arena Pharmaceuticals (Nasdaq: ARNA) announced the grant of inducement stock options and restricted stock units (RSUs) to six new employees on July 15, 2020. The total granted options amount to 35,850 shares, and 6,310 RSUs are offered, with a grant date and vesting commencement on the same day. The stock options have a seven-year term, an exercise price of $67.50, and vest over four years. The RSUs also vest over four years, aligning with the company's long-term incentive plan, aimed at attracting talent to execute its mission.
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced on June 15, 2020, the grant of inducement stock options for 80,250 shares and 12,360 restricted stock units (RSUs) to new employees. The stock options have a seven-year term with a $63.11 exercise price and vest over four years. RSUs also vest over four years. These grants are part of Arena's compliance with Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent to support the company’s growth and operational goals.
Arena Pharmaceuticals has appointed Dr. Katharine Knobil to its Board of Directors, enhancing its leadership team with over 20 years of experience in global clinical development and medical affairs. Dr. Knobil, currently CMO at Kaleido Biosciences, previously held key positions at GlaxoSmithKline, where she oversaw medical affairs and clinical safety. Arena's chairman, Tina S. Nova, expressed confidence that Dr. Knobil's expertise will significantly contribute to advancing the company's robust pipeline of therapies. The appointment aligns with Arena's commitment to delivering important medicines to patients.